A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Trofinetide (Primary)
  • Indications Concussion
  • Focus Therapeutic Use
  • Sponsors Neuren Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 27 Mar 2017 Status changed from suspended to discontinued.
    • 09 May 2016 Status changed from recruiting to suspended as data from another study requires re-evaluation of study design.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top